Abp 234 vs Camrelizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Abp 234

Developed by Amgen

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06430866 (registry estimate)

No aligned efficacy figure on record for this race.

Camrelizumab

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03134872 · Phase 3 · completed

CameL was a randomized, open-label Phase 3 trial in 419 patients with untreated non-squamous non-small-cell lung cancer without EGFR or ALK alterations, which compared camrelizumab plus carboplatin and pemetrexed with chemotherapy alone. It had two primary endpoints: progression-free survival in all patients and in PD-L1-positive patients. At the interim analysis, progression-free survival in all patients was significantly longer with camrelizumab (11.3 vs 8.3 months; hazard ratio 0.60). The paper reports confirmatory testing only for all patients, and no published result tests the PD-L1-positive primary, so the result is shown as unclear. The figures come from the peer-reviewed paper (Zhou et al., Lancet Respir Med 2021).

Next expected readout: December 2027 · NCT07016126 (registry estimate)

Reported efficacy

Progression-Free Survival in the intent-to-treat (ITT) population (up to 24 months); Progression-Free Survival in the PD-L1-selected population (up to 24 months): Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. (unclear)

Result source: NCT03134872

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAbp 234Camrelizumab
PFS, median—Trial running · NCT0643086611.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872
OS, median—Trial running · NCT06430866—Not posted · NCT03134872
ORR—Trial running · NCT0643086616.7%b375 mg · n 12NCT03083041
Duration of response, median—Trial running · NCT06430866—Not posted · NCT03134872

PFS, median

Abp 234
—Trial running · NCT06430866
Camrelizumab
11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872

OS, median

Abp 234
—Trial running · NCT06430866
Camrelizumab
—Not posted · NCT03134872

ORR

Abp 234
—Trial running · NCT06430866
Camrelizumab
16.7%b375 mg · n 12NCT03083041

Duration of response, median

Abp 234
—Trial running · NCT06430866
Camrelizumab
—Not posted · NCT03134872
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Abp 234: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Abp 234: 0 of 4 rows · Camrelizumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamrelizumab
Dropout rate
91.7%375 mga
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—375 mga
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
58.3%375 mga
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
56.6%250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
375 mga
rash 91.7%
hypertension 83.3%
decreased appetite 75%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
250 mg
hypertension 63.6%
proteinuria 63.1%
aspartate aminotransferase increased 53.5%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Camrelizumab

ORR 16.7% (n=12)375 mg
responder rate · % of participants
No placebo or comparator arm
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
PFS 11.3 vs 8.3 carboplatin + pemetrexed alone, PC months
time to event · months
NCT03134872 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abp 234's landscape · Camrelizumab's landscape